


GSK1034702

| | | | |
|---------------------------|--|-------|----------|
| Cat. No.: | HY-107111 | | |
| CAS No.: | 932373-87-0 | | |
| Molecular Formula: | C ₁₈ H ₂₄ FN ₃ O ₂ | | |
| Molecular Weight: | 333.4 | | |
| Target: | Cholinesterase (ChE) | | |
| Pathway: | Neuronal Signaling | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 2 mg/mL (6.00 mM; ultrasonic and warming and heat to 60°C)

| Concentration | Mass | | |
|---------------|-----------|------------|------------|
| | 1 mg | 5 mg | 10 mg |
| 1 mM | 2.9994 mL | 14.9970 mL | 29.9940 mL |
| 5 mM | 0.5999 mL | 2.9994 mL | 5.9988 mL |
| 10 mM | --- | --- | --- |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

GSK1034702 is a M1 mAChR allosteric agonist. GSK1034702 shows procognitive effects in rodents. GSK1034702 modulates hippocampal function to improve memory encoding in nicotine abstinence model of cognitive dysfunction^[1].

REFERENCES

[1]. Bradley SJ, et al. Bitopic Binding Mode of an M1 Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes. *Mol Pharmacol*. 2018 Jun;93(6):645-656.

[2]. Nathan PJ, et al. The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. *Int J Neuropsychopharmacol*. 2013 May;16(4):721-31.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA